To determine the possible mechanism(s) promoting alveolar fibrin deposition in the adult respiratory distress syndrome (ARDS), we investigated the initiation and regulation of both fibrinolysis and coagulation from patients with ARDS (n = 14), at risk for ARDS (n = 5), and with interstitial lung diseases (ILD) (n = 8), and normal healthy individuals (n = 13). Bronchoalveolar lavage (BAL) extrinsic pathway inhibitor activity was increased in ARDS BAL compared with patients at risk for ARDS (P = 0.0146) or normal controls (P = 0.0013) but tissue factor-factor VII procoagulant activity was significantly increased in ARDS BAL compared with all other groups (P < 0.001). Fibrinolytic activity was not detectable in BAL of 10 of the 14 patients with ARDS and low levels of activity were found in BAL of the other four ARDS patients. Depressed fibrinolysis in ARDS BAL was not due to local insufficiency of plasminogen; rather, there was inhibition of both plasmin and plasminogen activator. Plasminogen activator inhibitor 1 was variably detected and low levels of plasminogen activator inhibitor 2 were found in two ARDS BAL samples, but plasminogen activator inhibitor 2 was otherwise undetectable. ARDS BAL antiplasmin activity was, in part, due to a2-antiplasmin. We conclude that abnormalities that result in enhanced coagulation and depressed fibrinolysis, thereby predisposing to alveolar fibrin deposition, occur in the alveolar lining fluids from patients with ARDS.
Introduction
Alveolar fibrin deposition commonly accompanies human lung injuries such as pneumonitis and the interstitial lung diseases (1, 2) and is especially prominent in the adult respiratory distress syndrome (ARDS)' (3) . The importance of alveolar 1 . Abbreviations used in this paper: a2AP, a2-antiplasmin; ARDS, adult respiratory distress syndrome; AT III, antithrombin III; BAL, bronchoalveolar lavage; EPI, extrinsic pathway inhibitor; ILD, interstitial lung disease; PA, plasminogen activator; PAI-I and PAI-2, plasminogen activator inhibitors 1 and 2; PEEP, positive end-expiratory pressure; u-PA, urokinase.
fibrin deposition in the pathogenesis of pulmonary inflammation is currently unclear, but circumstantial evidence suggests the likelihood of an important role. Coagulation and extravascular fibrin may liberate cleavage products which are capable of potentiating the acute inflammatory response via effects on chemotaxis, vascular permeability, and immunomodulation (4-9). Activation of coagulation or fibrinolysis may, in turn, activate complement (10, 1 1), kinin-forming pathways (12) , and release of neutrophil elastase (12, 13) . In addition, fibrin deposits may influence the reparative response to acute lung injury. For example, inflammatory cells, including fibroblasts and macrophages, may aggregate upon fibrin matrices (14, 15) which may promote collagen deposition in vitro (16) . Persistent fibrin deposits may occur in areas of pulmonary scarring (17, 18) , further supporting the role of fibrin in pulmonary fibrosis. Studies of patients with ARDS and of experimental animals have further shown that extravascular, in particular, alveolar fibrin occurs in lung tissue in which fibrotic repair results after acute injury (1, 3, 19, 20) . These observations suggest that extravascular fibrin and disordered pathways of fibrin turnover may play an important role in the pathogenesis of both acute lung injury and repair. Delineation of local abnormalities that promote alveolar fibrin deposition is therefore germane to understanding the pathogenesis of ARDS.
Abnormalities in the pathways of fibrin turnover occur in alveolar lining fluids in association with lung diseases in humans and pneumonitis in experimental animals (19) (20) (21) (22) (23) . Cells harvested from bronchoalveolar lavage (BAL) ofpatients with interstitial inflammation due to idiopathic pulmonary fibrosis and sarcoidosis have increased procoagulant activity and decreased fibrinolytic activity when compared with normal healthy controls (23) . In rabbits treated with phorbal myristate acetate, increased BAL fibrinolytic activity was found to correlate with the clearance of alveolar fibrin from the injured lung (2) . We have shown that increased procoagulant activity occurs in the BAL ofpatients with ARDS (21) and marmosets with bleomycin-induced lung injury in which prominent alveolar fibrin deposition occurred (19) . These studies suggest that abnormalities of coagulation and/or fibrinolysis which occur in alveolar lining fluids may influence fibrin deposition associated with alveolar inflammation. In this study, we document the concomitant increase in coagulation with a decrease in fibrinolysis in the alveolar fluids of patients with ARDS and characterize the mechanisms responsible for the observed abnormalities of fibrin turnover. Methods and 13 were normal healthy control subjects with no evidence of mechanically ventilated at the time of the BAL procedure and three pulmonary disease. Of patients at risk for ARDS, two went on to were being hemodynamically monitored. Two ofthese patients (Nos. 7 develop the syndrome, were studied after ARDS had developed, and and 13) were initially in the at-risk group but later went on to fulfill were included in the ARDS group. Bronchoscopy and BAL were percriteria for ARDS by the time of BAL. The other five patients did not formed after informed consent was obtained from each subject or develop ARDS (Table I) . nearest relative. The study protocol was approved by the Institutional Analysis ofthe severity ofillness ofpatients with ARDS and at risk Review Board ofthe Veterans Administration Medical Center, Seattle, for ARDS. The severity of illness of patients with ARDS at the time of WA. Criteria for patient selection and clinical characteristics of these BAL was assessed using several different scoring systems. Oxygenation groups are given in the subsections below.
and radiographic and compliance scores were developed according to ARDS. All patients were studied within 3 d of recognition of the classification systems developed by Weinberg and colleagues (24) ARDS. Patients ranged in age from 19 to 84 yr. Five patients had and a composite severity score was then developed based on these underlying sepsis; the remainder had other underlying conditions that analyses. The radiographic score of the severity of pulmonary infilincluded aspiration pneumonitis, multiple trauma, and drug overdose.
trates was tabulated as previously reported by Weinberg et al. (24) . In All of the patients with ARDS were mechanically ventilated while the addition, an oxygenation score, or Pao2/Fio2 ratio (P/F), was deter-BAL procedure was performed and in no case did the patient appear to mined (24), where Fio2 = fractional concentration of inspired oxygen be adversely affected by the procedure. ARDS was defined as the and Pao2 = partial pressure of oxygen in arterial blood. The following sudden onset of respiratory failure associated with refractory hypoxweighted score was used to quantitate the abnormality in gas exchange emia, and arterial P02 of. 60 with a fractional inspired oxygen (Fio2) or 02 score: 0, P/F > 265; 1, P/F = 200-264; 2, P/F = 135-199; 3, P/F of . 60% and widespread diffuse infiltrates over the lungs on chest = 70-134; 4, P/F < 70. If the Pao2/Fio2 ratio was measured during
x-ray (21, 22) . Pulmonary capillary wedge pressure was measured after positive end-expiratory pressure (PEEP) therapy (PEEP > 10 cm H20), placement of a Swan-Ganz catheter and was < 18 mm Hg in all cases.
one point was added to the gas exchange score (up to a maximum of4). Clinical data for patients with ARDS and those at risk for ARDS are Selected parameters, including the mean pulmonary artery pressure, shown in Table I. pulmonary artery wedge pressure, and bedside lung compliance (data Patients at riskforARDS. Five patients who were considered to be not shown) were also determined immediately before BAL in patients at risk for ARDS, by virtue of having underlying multiple trauma with with ARDS. A respiratory system compliance score was calculated in extensive tissue injury, were studied. All of these patients were being patients receiving mechanical ventilation as the corrected tidal volume Normal control subjects. 13 young, healthy individuals with no known pulmonary disease served as normal controls. All of these subjects were nonsmokers with an age range of 21-30 yr.
BAL samples and preparation. BAL was performed and processed as previously described (21) . The lavage procedure was well tolerated in all patient groups with recovery of -50% of the instilled fluid (coefficient of variation equals -20%). Total protein content of BAL was determined using bicinchoninic acid (Pierce Chemical Co., Rockford, IL). Total BAL cell count of the resuspended cell pellet was obtained by a counter (Coulter Electronics, Inc., Hialeah, FL) and BAL differential white cell count was done after cytocentrifugation.
Coagulation assays. BAL was exposed to normal pooled plasma (George King, Inc., Overland Park, KS) and the recalcification time in the presence of 8.3 mM CaCl2 was determined as previously described (19, 21) . Interassay variation was < 6%, as previously reported (21) and BAL procoagulant activity was determined to be stable at -700C for at least I yr. All assays were performed in duplicate using the same lot of plasma. The recalcification times of BAL were converted to procoagulant unit equivalence, based upon the recalcification times generated by tissue factor standards, where 100,000 U of procoagulant activity was defined as the recalcification time generated by 100 Ml of a I -mg/ ml suspension of rabbit brain thromboplastin (American-Dade, Aquada, Puerto Rico).
To determine the activity attributable to the extrinsic pathway inhibitor, we used the three-stage coagulation assay described by Broze and Miletich (26) . A standard curve was constructed using pooled normal human plasma and a linear relationship was observed between the log of the clotting time and the log of plasma concentration (0.1-8% plasma). All BAL samples were undiluted and assayed in duplicate.
Amidolytic assay offactor Xa. Conversion of factor X to Xa by BAL was determined by an amidolytic assay performed in duplicate as previously described, with slight modifications (21) counted. The 48-h time course was chosen to enhance the sensitivity of the assay required for the study ofunconcentrated BAL samples. Fibrinolytic activity generated by BAL or urokinase standards (American Diagnostics, Inc., Greenwich, CT) was found to be sigmoidal and not linear over time and the PA activity ofBAL was based upon the time at which 50% of releasable radioactivity was achieved. The PA activity in international units per milliliter (IU/ml) ofeach sample was calculated from the urokinase standard curve which had a sensitivity of 0.0049
Fibrin gel autography. Fibrin gel autography was performed as described by Levin et al. (30) . Briefly, prestained high molecular weight standards, BAL, or urokinase (u-PA) standards were subjected to SDS-10% polyacrylamide gel electrophoresis (SDS-PAGE), and the gel was soaked in 0.1 M sodium phosphate, pH 7.2, with 2.5% Triton X-100, blotted dry, and placed on top of a freshly prepared fibrin indicator gel. The indicator gel was allowed to develop at room temperature in a moist chamber, and then photographed.
Reverse fibrin gel autography. Reverse fibrin gel autography was performed as previously described (31) . Samples were subjected to SDS-PAGE, and the gel was soaked in 2.5% Triton X-100 to neutralize the SDS and then placed over a fibrin-agar indicator plate containing 0.075 IU/ml of urokinase. Formation of opaque, lysis-resistant zones in the clear, lysed indicator gel indicated regions in the gel containing the PA inhibitor.
Antiplasmin activity. Antiplasmin activity was measured by mixing equal volumes (325 Ml) of 5 Ag/ml plasmin (American Diagnostics, Inc., New York) diluted in normal saline with saline alone or BAL samples for 30 min at 37°C. Residual fibrinolytic activity was determined by the '25I-fibrin plate assay described above. Goat antibody to human a2-antiplasmin (a2AP) and control goat IgG (purchased from American Diagnostica) were bound to Affigel-lO beads (Bio-Rad Laboratories, Richmond, CA), according to the manufacturer's instructions at a ratio of 5 mg of antibody per milliliter of resin. a2AP (American Diagnostica) was used to characterize the immobilized antibody. The beads were then used to adsorb BAL samples of antiplasmin activity. BAL (325 Ml) was incubated with either anti-a2AP or control beads bound to normal goat IgG 1:1 (vol/vol) for 1 h at room temperature. The beads were then centrifuged by a flash spin (Microfuge, Beckman Instruments, Inc., Fullerton, CA) and 325
Ml of supernatant added to 325 Ml of plasmin standard (1.25 ,g/ml). After incubation for 30 min at 37°C, the resultant plasmin-mediated fibrinolytic activity was determined in the fibrin plate assay.
Measurement ofplasminogen, a2AP, plasminogen activator inhibitor 2 (PAI-2) and antithrombin III (A TIII). Double-antibody competitive equilibrium RIA were modified from those previously reported for human plasminogen and a2AP (32) . Proteins were radioiodinated by the dilute chloramine-T method (27) to specific activities of 1.7-6.6
MCi/Mg. To 250 Al of labeled protein (0.5 nM) was added 250 M1 of competing human protein (for standard curve) or BAL fluid (diluted 1:4) and 250 ,l of rabbit antibody diluted to give -30% binding ofthe iodinated ligand. After incubation at 4°C for 16-20 h, 500 Ml of goat anti-rabbit IgG (Pel-Freez Biologicals, Rogers, AR) was added and incubated at 4°C for 6 h. The immunoprecipitates were collected by centrifugation at 2,000 g for 15 min, and 500 Ml of supematant was counted in a gamma counter. In control studies, the regression lines on semilogarithmic plots of the inhibition of '251-protein binding to its specific antibody by normal BAL fluid were parallel to the competition curves observed for the purified protein and normal human plasma permitting an estimate of their concentration in BAL. The buffer used for the assay contained 50 mM Tris-HCI (pH 8.0), 25 mM NaCl, 10 mM benzamidine, 1 mM phenylmethylsulfonyl-fluoride, 5 U/ml aprotinin, 0.75% normal rabbit serum, and 0.02% NaN3. Rabbit antibodies to human plasminogen and a2AP were generously provided by Drs. Edward F. Plow and Lindsey A. Miles (Research Institute of Scripps Clinic).
An RIA for PAI-2 was carried out according to Kruithof et al. (32) . Dr. Kruithof (Laboratoire Centrale d'Hematologie, Lausanne, Switzerland) was kind enough to supply us with purified PAI-2, as well as the specific antiserum (33). PAI-2 was iodinated by the iodogen method (34) . Standard curves for the RIA were constructed using PAI-2, and PAI-2 complexed to urokinase (u-PA). The standard curves generated by PAI-2 alone or PAI-2 complexed to u-PA (complete complex formation verified by SDS-PAGE and autoradiography of iodinated proteins) demonstrated that the RIA detected PAI-2 complexed to u-PA, as well as it detected free PAI-2 (35) . The BAL samples were analyzed undiluted and diluted in 0.2 M NaCl, 10 mM EDTA, 50 mM Tris-HCL, pH 7.4, 0.1% BSA. Samples were incubated 4 h at room temperature with an equal volume of rabbit anti-human PAI-2 IgG, (9 gg/ml). 50 jul of 1251-PAI-2 containing 2,100 cpm was added, and the mixtures were incubated with rotation overnight at 4°C. Antigen-antibody complexes were precipitated by a 30-min incubation at room temperature with 100 IA of a 30% suspension ofgoat anti-rabbit IgG linked to agarose beads (Sigma Chemical Co.). The mixtures were centrifuged, the agarose beads were washed three times with 2 ml of 0.15 M NaCl, and radioactivity bound to the agarose beads was counted in a gamma counter (Beckman Instruments, Inc., Irvine, CA). In control experiments, BAL samples were supplemented with known amounts of purified PAI-2 and analyzed by RIA. Competition curves generated by these samples were parallel to the standard curve.
AT III was measured by RIA as we have previously reported (36) . Factor Xa inhibiting activity of BAL was measured using the previously described amidolytic assay of factor Xa (21) . Briefly, 100 ng of factor Xa in 5.5 ul 0.15 M NaCl, 0.02 M Tris, pH 7.4 (Tris-buffered saline [TBS] ) was added to 150 ,l of TBS containing I mg/ml BSA or BAL and the mixture was incubated at 37°C for 30 min. Duplicate 75-Ml aliquots were then removed for amidolytic analysis as described above. Amidolytic activity was expressed as nanogram per milliliter equivalents based on a factor Xa standard curve and residual activity after incubation with BAL was presented as a percentage ofthe activity obtained with the TBS-BSA blanks.
ELISA assay for plasminogen activator inhibitor 1 (PAI-I). Concentrations of PAI-l were determined by an ELISA assay as follows: 96-well microtiter plates were coated with 10 ug/ml rabbit anti-human PAI-I diluted in 50 mM sodium borate, pH 9.0, at 4°C overnight and washed with wash buffer PBS, 0.05% Tween 20, 0.1% BSA. Samples or standards were diluted into PBS containing 0.05% Tween 20 and 1% BSA, and 100-Ml aliquots were incubated in the coated wells for 2 h at room temperature. The plates were washed with wash buffer, and 0.25 Mg/ml monoclonal antibody to PAI-I (No. I 105, Monozyme, Lyngby, Denmark) diluted into wash buffer containing 0.1% bovine globulin was added to the wells and incubated for 2 h at room temperature. After washing, the wells were incubated with a 1:2,000 dilution of horseradish peroxidase-conjugated rabbit anti-mouse IgG (Caltag, Burlingame, CA) for 2 h, and washed again, and substrate was added. Plates were read after 45 min of incubation. This assay detects both free inhibitor and inhibitor in complex with tPA (data not shown).
Standard curves for PAI-l assays were determined by log-logit transformation of the binding reaction which gave a linear dose response in the range of 0.8-25 ng/ml PAI-1.
Detection ofurokinase. Immunoblotting for u-PA was carried out as previously described (37 (21) . We therefore compared levels of factor X-activating activity in BAL of patients with ARDS and each of the control groups in order to gauge the relative expression of procoagulant activity related to the extrinsic coagulation pathway. BAL factor X-activating activity was found to be increased in patients with ARDS [median 1.24 pmol/(min. ml)] compared with normal control individuals [median 0.21 pmol/ (min * ml), P = 0.0003] or patients with interstitial lung disease [median 0.38 pmoles/(min -ml), P = 0.0033]. Although a trend towards lower levels of factor X-activating activity was present in BAL of patients at risk for ARDS [median 0.60 pmol/(min * ml)] the levels did not achieve a statistical significance (P = 0.069) vs ARDS BAL. We were unable to detect factor Xa activity in any BAL samples by amidolytic assay in the absence of supplemental factor X.
Levels of extrinsic pathway inhibitor (EPI) were likewise increased in ARDS BAL (median 0.68 ng/ml) compared-with patients at risk for the syndrome (median 0.17 ng/ml, P = 0.0 146) or normal healthy controls (median 0.18 ng/ml, P = 0.0013). Increased levels of EPI activity were detected in some patients with ILD (median 0.61 ng/ml), but did not significantly differ from levels in BAL of patients with ARDS (P = 0.59). Although the EPI was increased in ARDS, it is appeared to be insufficient in controlling the increased procoagulant activity attributable mainly to tissue factor associated with factor VII. In contrast, the EPI appeared to effectively control the procoagulant activity present in ILD.
Antigenic levels of AT III were significantly increased in ARDS BAL (median 236.7 ng/ml) vs. normal controls (median 24.2 ng/ml, P = 0.0020) or patients with ILD (median 8.4 ng/ml, P = 0.0020) and levels measured in BAL of patients at risk for ARDS (median 161.3, P = 0.27) did not significantly differ from those with ARDS. In contrast, the factor Xa-inhibiting activity of ARDS BAL was low and did not significantly differ from that determined for any of the control groups (data not shown). In patients with ARDS, BAL levels of AT III were significantly correlated with BAL total protein (r = 0.6933, P = 0.0004) suggesting that the increased levels of this inhibitor in ARDS BAL reflects the extravasation of plasma proteins into the alveolar space.
Characterization and quantitation ofthefibrinolytic activity present in BAL. As shown in Fig. 1 The molecular weight analysis of the PA present in BAL was next investigated by fibrin gel enzymography. In normal BAL samples the major zone of fibrinolytic activity was found to comigrate with the 50,000-mol wt urokinase (u-PA) standard, when the fibrin indicator gel contained plasminogen (Fig. 2 a) . The u-PA concentrations in all BAL samples were beneath the 0.1 ng/ml sensitivity of our ELISA assay and attempts to detect u-PA in unconcentrated BAL samples by immunoblotting assays were also unsuccessful. However, the assumption of urokinase-like PA activity in BAL is based on the molecular weight and antibody neutralization observations reported by others (23, 41) . By fibrin gel enzymography, the 50,000-mol wt zone of fibrinolysis was either attenuated or absent in ARDS BAL (n = 13 samples studied) in which fibrinolytic activity was found to be depressed in the '251I-fibrin plate assay. This activity was, by contrast, detectable by enzymography in BAL of patients at risk for ARDS (n = 5), those with ILD (n = 4), and normal controls (n = 7). (Fig. 2 a) . Lytic zones of higher molecular weight were generated by ARDS BAL and corresponded to 90,000 and 70,000 mol wt (Fig. 2 a) . When plasminogen was deleted from the enzymography plates, fibrinolysis was absent at the 50,000-and/or 70,000-mol wt zones in all BAL samples (Fig. 2 b) . Thus, these activities were plasminogen dependent and suggest that the 70,000-mol wt form was attributable to urokinase-like PA bound to an inhibitor, as may be detected in this assay system (42) . The 90,000-mol wt zone persisted in the absence of plasminogen indicating the presence of plasminogen-independent fibrinolytic activity in these BAL samples. It appeared that the concentrations of this PA were too low to be detected in the fibrin plate assay or that this active molecular weight species may also represent an inactive enzyme-inhibitor complex under nondenaturing conditions. Determination of (PAls) was undertaken to further characterize these complexes as well as to document their presence in BAL. Control BAL samples and those from at-risk patients did not contain PAI activity using reverse fibrin autography consistent with the presence of relatively high levels of u-PA activity (Fig. 3) . However, in patients with ARDS, lysis-resistant zones were identified at 46,000 mol wt, indicating the presence of PAI (Fig. 3) .
Because the molecular weight ofPAI activity was similar to that of PAI-1 secreted from Hep G2 cells (43), we performed antibody neutralization experiments to identify which PAI molecule was present in the BAL from ARDS patients. Samples of ARDS BAL were electrophoresed in parallel with conditioned medium from Hep G2 cells and the PAI activity was observed by reverse enzymography plates impregnated with 700 either normal IgG or monospecific antibody to PAI-1. As shown in Fig. 4 , the lysis-resistant zones identified in ARDS BAL as well as Hep G2 cells supernatants were inhibited in the presence of antibody to PAI-1. In addition, these samples were found to contain increased concentrations of PAI-1, as measured by ELISA assay (data not shown). Elevated levels of PAI-l were variably found in BAL of 5 of 14 patients with ARDS (range 6.4-28.4 ng/ml) and one patient at risk for ARDS (6.4 ng/ml). Increased PAI-l antigens in these BAL fluids paralleled increased PAI activity by reverse fibrin autography (Figs. 3 and 4) . Conversely, BAL lacking detectable antigenic PAI-l had no detectable PAI activity which could be detected by reverse autography. Very low concentrations of PAI-2 were identified in two of the patients with ARDS and were not found in BAL of any ofthe other patient groups. The lack of demonstrable PAI-2 in all of these BAL samples was not due to the assay in that supplemental amounts of PAI-2 (10-100 ng) added to BAL samples lacking detectable antigen were quantitatively recovered (data not shown).
We next investigated whether the lack of fibrinolytic activity in ARDS BAL was attributable to insufficient quantities of plasminogen in these fluids. The concentration of plasminogen was significantly increased in BAL from patients with ARDS as compared with any of the control groups (Fig. 5) .
Whereas low concentrations of plasminogen were detected in BAL of normal controls and patients with ILD, BAL from patients at risk for ARDS contained higher levels of the proteins. Thus, sufficient substrate for the PA was available in the BAL of ARDS patients.
We next sought to determine the physical state of the plasminogen substrate which would be available to participate in fibrinolytic reactions in ARDS BAL. Plasminogen derivatives were isolated from BAL using immune absorption and the plasminogen-related proteins were separated by SDS-PAGE, transferred to nitrocellulose, and localized by immunoblotting (Fig. 6) . The principal form ofplasminogen in ARDS BAL was the Glu-1-plasminogen (92,000 mol wt). Activation of the native protein to Lys 77-plasminogen (83,000 mol wt) was not detected in the BAL samples but the A chain of plasmin (Lys 1-4) or rabbit anti-PAI-I (lanes 5-8) . 77-Arg 560; 56,000 mol wt) was detectable in ARDS BAL samples. BAL of normal individuals, patients at risk for ARDS, and patients with ILD likewise were found to contain Glu-l plasminogen. In the ARDS as well as control BAL, higher molecular weight immunoreactive species were observed, and may represent plasmin-inhibitor complexes. To determine if inhibition ofgenerated plasmin could contribute to the depressed fibrinolytic activity associated with ARDS, we incubated BAL from ARDS patients with purified plasmin at concentrations predetermined to exceed the highest levels of PA-derived plasmin activity present in BAL of normal healthy control individuals. Nearly all of the fibrinolytic activity generated by 2.5 and 5 ,ug/ml plasmin standards in the 1251I-fibrin plate assay was attenuated (mean 74.1% and 82.7% inhibition, respectively) by the addition of BAL samples (n = 6) from patients with ARDS, indicating the presence of an active inhibitor of plasmin (data not shown). In comparative experiments, equal volumes of 1.25 ,ug/ml of plasmin and normal saline or BAL from each of the four groups were incubated for 30 min at 37°C and the residual plasmin activity measured by the fibrin plate assay. As shown in Fig. 7 , little antiplasmin activity was identified in normal control BAL. Somewhat increased antiplasmin activity was present in BAL of patients at risk for ARDS (median 0.500 IU/ml, P = 0.67) and those with ILD (median 0.507 IU/ml, P = 0.20), relative to normals (Fig. 7) . The antiplasmin activity of ARDS BAL was significantly increased (-10-fold greater) compared to any of the control groups.
To characterize the antiplasmin activity contributing to the depressed fibrinolytic activity in BAL of patients with ARDS, we absorbed three BAL samples which contained no detectable fibrinolytic activity with antibody to a2AP or control IgG immobilized to Affigel-10 beads. The absorbed samples were then tested for their ability to neutralize 1.25 ,g of plasmin in 
Discussion
Tissue fibrin deposition represents the net effect of coagulation, which promotes fibrin formation, and fibrinolysis, which promotes fibrin dissolution. In previous studies, procoagulant activity attributable to components of the extrinsic coagulation pathway has been described in the alveolar compartment of man and experimental animals (2, 19, 21, 23, (43) (44) (45) (46) (47) (48) . In addition, fibrinolytic activity attributable to urokinase or urokinase-like PA has been described in BAL and macrophages from the lower respiratory tract of humans and animals (23, 41, 49, 50) . Under normal circumstances, little procoagulant activity (21, 47, 48) and relatively high levels of fibrinolytic activity (23, tologic hallmark of ARDS (3), and can be a prominent feature of the ILD and pneumonitides (1, 2). These observations suggest that the normal homeostasis of coagulation and fibrinolytic processes is disturbed in human lung injury and that conditions that promote fibrin deposition are established in the alveolar compartment.
In this study, we found that the balance of BAL procoagulant and fibrinolytic activities was most disrupted in patients with ARDS, as assessed by depression of fibrinolytic activity uniformly associated with increased procoagulant, antiplasmin, and PAI-I activity in BAL. Although the potent inhibitor of the extrinsic coagulation pathway, EPI, and AT III locally increased, they are present in insufficient quantities to counter the enormous procoagulant potential of the ARDS BAL. Further, there is a discordance between AT III concentrations (elevated) and activity (normal) in ARDS BAL. Presumably, this inhibitor is complexed with factor Xa or thrombin and is unavailable to further regulate increases in these reactants generated by more proximal procoagulants. The aggregate effect of these abnormalities would be expected to promote alveolar fibrin deposition in ARDS. The severity of alveolitis was greatest in ARDS patients based upon multiple criteria including significant elevations (23) and suggest a putative mechanism by which alveolar fibrin forms in the interstitial diseases as previously described (1, 23 Impaired fibrinolytic activity present in BAL of patients with ARDS was found to be due to effective inhibition of both plasmin and PA, rather than a lack of the PA substrate, plasminogen. Native Glu-plasminogen was easily detected in the BAL of ARDS patients, but little plasmin was observed. Sufficient antiplasmin activity was present in BAL to account for inhibition of all fibrinolytic activity generated by the PA found in normal BAL samples. Antiplasmin activity of ARDS BAL was found to be due in part to a2AP. a2AP or PAI-l was generally undetectable in BAL samples of control individuals. It is therefore likely that these circulating inhibitors gain entry to the alveolar space as a result of microvascular injury associated with ARDS.
The role of coagulation, fibrinolysis, and tissue fibrin deposition in the pathogenesis of ARDS is currently unclear. However, lung injury may be induced by the intravenous administration of procoagulants with or without concomitant inhibition of fibrinolysis (51) (52) (53) , and catabolism of fibrinogen or fibrin may generate peptides which potentiate inflammatory reactions in the injured lung (4) (5) (6) (7) (8) (9) . Further, evidence has been accumulated that fibrin may influence lung repair after acute injury. In bleomycin-challenged marmosets, we found that parenchymal, primarily alveolar fibrin deposition was temporally associated with histologic and biochemical evidence of pulmonary fibrosis (19) . In humans, persistent fibrin deposition has been found at foci of pulmonary fibrosis in two separate pathologic studies (17, 18) . In normal wound healing, extravasated procoagulants interact with locally expressed tissue factor to promote fibrin formation which subsequently organizes to form mature scar tissue (54) . If, by analogy, these processes occur in the severely injured human lung, then abnormalities of the procoagulant-fibrinolytic balance may figure importantly in the development of accelerated pulmonary fibrosis (or parenchymal fibrosis of lesser severity) which contributes to morbidity and mortality in ARDS.
In summary, we found that enhanced procoagulant activity is associated with severely impaired or absent fibrinolytic activity in BAL of patients with ARDS. Similar but less profound abnormalities may occur in patients at risk for ARDS and those with chronic pulmonary inflammation associated with ILD, predisposing these patients to alveolar fibrin deposition. Expression ofincreased procoagulant activity due mainly to tissue factor associated with factor VII occurs in ARDS BAL despite increases in AT III and EPI, whereas fibrinolytic activity is markedly depressed by a dual mechanism ofinhibition of both plasmin and PA, effected, in part, by a2AP, PAI-1, and to a lesser extent, PAI-2. These concurrent abnormalities effectively reverse the normal balance of pathways of fibrin formation and dissolution in the lower respiratory tract of ARDS patients and establish conditions that promote the extensive alveolar fibrin deposition which is characteristically found in the lungs in ARDS. These observations most likely represent only part ofthe overall regulation of fibrin turnover in ARDS, as cell-cell interactions and cell surface assembly sites may assume important regulatory functions. However, the changes present in BAL reflect the net effects of soluble mediators released into the microenvironment of the injured lung in ARDS, presumably by several cell types that participate in the local inflammatory response. The changes in pathways of fibrin turnover indentified in ARDS BAL may be strongly inferred to influence alveolar fibrin deposition in that the exudative fluids that bathe and persist within the alveoli in ARDS promote fibrin deposition and retard its clearance.
